Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared a post by Mali Barbi, Medical Oncologist at Northwell Health, on X, adding:
”A challenge is that we have no ideal neoadj regimen:
- carbo in TCHP may not improve pCR
- no mature EFS with THP alone
- T-DXd-THP highly active but not powered on EFS
My recommended approach is depicted in this figure.
More nuance in our upcoming podcast.”
Quoting Mali Barbi‘s post:
”Tumor Board Dilemma:
T-DXd is now FDA-approved neoadjuvantly (DB-11).
It drives high pCR, but SATEEN/A3 confirmed if they recur, you prob face pan-TOPO1 resistance with zero salvage.
Where are you actually drawing the line for early-stage HER2+ breast cancer today?”
Other Articles Featuring Paolo Tarantino and Mali Barbi On OncoDaily.